Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
R647182-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $500.90 | |
R647182-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $850.90 | |
R647182-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,800.90 | |
R647182-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $3,000.90 | |
R647182-100mg | 100mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $4,600.90 |
Synonyms | Risarestat|79714-31-1|CT 112|Risarestat [INN]|CT-112|Risrestat|5-(3-Ethoxy-4-(pentyloxy)phenyl)thiazolidine-2,4-dione|2,4-Thiazolidinedione, 5-(3-ethoxy-4-(pentyloxy)phenyl)-|6I9DQB98QI|DTXSID7048796|Risarestat (INN)|5-[3-ethoxy-4-(pentyloxy)phenyl]-2,4-t |
---|---|
Specifications & Purity | ≥98% |
Biochemical and Physiological Mechanisms | Risarestat (CT-112), an aldose reductase inhibitor, is developed for the treatment of diabetic complications. |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Product Description | Risarestat (CT-112), an aldose reductase inhibitor, is developed for the treatment of diabetic complications. In Vivo Risarestat inhibits the accumulation of dulcitol in a dose-dependent manner, except for the 1.0% solution which has an activity comparable to the 0.25% solution . Risarestat peaks in the corneal epithelium, stroma, endothelium and aqueous humor in 30 minutes following instillation, then gradually diminishes time-dependently over a period of 24 hours. Risarestat remains detectable in the lens up to 24 hours, with a peak concentration at 2 hours after instillation. The anterior surface area of superficial cells in the group treated with Risarestat is significantly decreases from a mean value of 881 to 728 microns 2 . Corneal sensitivity significantly improves from 5.36 to 1.37 g/mm 2. Animals treated with Risarestat shows a significant increase in the mean blinkresponse compared to untreated galactose-fed rats and does not differ significantly from controls towards the completion of the 7 month study. Animals treated topically with Risarestat and untreated galactose-fed rats develop bilateral nuclear cataracts within 3 weeks. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 5-(3-ethoxy-4-pentoxyphenyl)-1,3-thiazolidine-2,4-dione |
---|---|
INCHI | InChI=1S/C16H21NO4S/c1-3-5-6-9-21-12-8-7-11(10-13(12)20-4-2)14-15(18)17-16(19)22-14/h7-8,10,14H,3-6,9H2,1-2H3,(H,17,18,19) |
InChi Key | CRPGRUONUFDYBG-UHFFFAOYSA-N |
Canonical SMILES | CCCCCOC1=C(C=C(C=C1)C2C(=O)NC(=O)S2)OCC |
Isomeric SMILES | CCCCCOC1=C(C=C(C=C1)C2C(=O)NC(=O)S2)OCC |
Alternate CAS | 79714-31-1 |
PubChem CID | 133264 |
MeSH Entry Terms | 5-(3-ethoxy-4-pentyloxyphenyl)-2,4-thiazolidinedione;CT 112;CT-112;risarestat |
Molecular Weight | 323.41 |
Enter Lot Number to search for COA:
Solubility | DMSO : 105 mg/mL (324.67 mM; Need ultrasonic) |
---|